HONG KONG – In the wake of a couple of incidents that have highlighted holes in China’s drug traceability and distribution systems, the country’s drug regulation has put forward a series of regulatory revisions.
HONG KONG – Looking to continue morphing from a maker of active pharmaceutical ingredients (APIs) to a key biologic drug developer and manufacturer, Zhejiang Hisun Pharmaceutical Co. Ltd. has bought the rights to a targeted therapy for epithelioma in China from U.S. biotech company Nascent Biotech Inc.
HONG KONG – Looking to continue morphing from a maker of active pharmaceutical ingredients (APIs) to a key biologic drug developer and manufacturer, Zhejiang Hisun Pharmaceutical Co. Ltd. has bought the rights to a targeted therapy for epithelioma in China from U.S. biotech company Nascent Biotech Inc.
HONG KONG – With a green light from the CFDA, Taiwan antibiotics maker Taigen Biotechnology Co. Ltd. now has the first made-in-Taiwan novel drug marketed in mainland China.
HONG KONG – With a green light from the CFDA, Taiwan antibiotics maker Taigen Biotechnology Co. Ltd. now has the first made-in-Taiwan novel drug marketed in mainland China.
